GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

Sanofi

GoodRx said on Thursday it has collaborated with Sanofi to offer the drugmaker's most-prescribed insulin injection Lantus for only $35 through its digital marketplace in the U.S.

GoodRx to offer Sanofi's insulin injection for only $35

The effort comes after Sanofi, Eli Lilly and Novo Nordisk announced sweeping insulin price cuts earlier this year.

Sanofi to offer insulin product for $35 to all Americans through GoodRx

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is working with Sanofi (NASDAQ: SNY), a global leader in diabetes care, to offer a new way for people living with diabetes to access Lantus® (insulin glargine injection) 100 Units/mL in the U.S. for only $35. This collaboration builds on Sanofi's recent announcement to lower the list price for Lantus and cap out-of-pocket costs at $35 for all patients with.

GoodRx Announces New Way for Consumers to Access Sanofi's Lantus for $35 at Over 70,000 Pharmacies Nationwide

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), a leading resource for healthcare savings and information, today announced it will release its third quarter 2023 financial results before U.S. markets open on Thursday, November 9, 2023. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the confer.

GoodRx Announces Date for Third Quarter 2023 Earnings Release and Conference Call

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, and Navitus Health Solutions, LLC, a pass-through pharmacy benefit manager (PBM) committed to removing cost from the drug supply chain, today announced the launch of Savings Connect. This program, when elected by clients, provides members with automatic access to GoodRx prices on generic drugs in a seamless experience at the pharmacy counter. Consumers no longer have to proac.

GoodRx and Navitus Health Solutions Announce Savings Connect Program to Deliver Lower Prescription Prices for Navitus Members

GoodRx's investment thesis is positive. The company's near-term prospects are promising. GoodRx is experiencing strong revenue growth rates.

GoodRx Faces Challenges In Subscription Plans, But Its Valuation Already Prices This In

GoodRx is generating solid profitability with growth in monthly active consumers to its prescription drugs discount platform. Management expects stronger trends into the second half of the year. The stock has been under pressure since the last quarterly report, although we see value at the current level with room for shares to rebound going forward.

GoodRx Stock: Earnings Momentum Keeps It Interesting

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is offering new savings on antivirals, medications and vaccines for the upcoming cold and flu season. Last flu season (October 1, 2022 through April 30, 2023), the CDC estimates that influenza was associated with more than 27 million illnesses, 300,000 hospitalizations, and 19,000 deaths, showing the importance of Americans taking preventative measures to p.

GoodRx Announces Significant Savings on Antivirals, Medications and Vaccines for Cold & Flu Season

The heavy selling pressure might have exhausted for GoodRx Holdings, Inc. (GDRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -11.5% in 4 Weeks, Here's Why You Should You Buy the Dip in GoodRx Holdings, Inc. (GDRX)

MedImpact and GoodRx have partnered to deliver lower prices on prescriptions at the pharmacy counter.  The collaboration will integrate GoodRx's prescription pricing into MedImpact's pharmacy benefit manager (PBM) services, providing a seamless experience for MedImpact members at the pharmacy counter, the companies said in a Wednesday (Sept.

GoodRx and MedImpact Collaborate on Lower Drug Prices

SANTA MONICA, Calif. & SAN DIEGO--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, and MedImpact, the independent pharmacy benefit manager (PBM) and health solutions company, today announced a new savings solution designed to integrate GoodRx's prescription pricing in a seamless experience at the pharmacy counter. Now, when an eligible MedImpact member fills a prescription for a generic medication, it will automatically compare their benefit and.

GoodRx and MedImpact Announce Program to Ensure Seamless Access to Affordable Prescriptions

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced a new initiative at Walgreens to reduce prices on nearly 200 prescription medications by an average of 40%, with even greater savings available for select medications. Consumers can now purchase many popular prescriptions at Walgreens for less than $15 for a 30-day fill, without any deductibles, restrictions, paperwork, approvals or quantity limitations. The n.

GoodRx Now Offers 40% More Savings on Nearly 200 Medications at Walgreens

ICON

Investors interested in stocks from the Medical Services sector have probably already heard of Icon PLC (ICLR) and GoodRx Holdings, Inc. (GDRX). But which of these two companies is the best option for those looking for undervalued stocks?

ICLR vs. GDRX: Which Stock Should Value Investors Buy Now?

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading resource for healthcare savings and information, today announced that executives from the Company will be presenting at the Morgan Stanley Global Healthcare Conference in New York, NY on Wednesday, September 13, 2023 at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time). A live webcast of the presentation will be available on the Company's Investor Relations website, https://investors.goodrx.com/. Following the.

GoodRx to Present at the Morgan Stanley Global Healthcare Conference

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced the launch of real-time benefit check (RTBC) in Provider Mode. Developed in collaboration with AssistRx, the advanced therapy initiation and patient solutions provider, real-time benefit check gives healthcare professionals (HCPs) immediate access to eligible patients' insurance coverage and greater visibility into the cost of brand and specialty drug prescrip.

GoodRx Launches Real-Time Benefit Check In Provider Mode To Offer Comprehensive Cost Information At The Point of Prescribing

Investors looking for stocks in the Medical Services sector might want to consider either Icon PLC (ICLR) or GoodRx Holdings, Inc. (GDRX). But which of these two companies is the best option for those looking for undervalued stocks?

ICLR or GDRX: Which Is the Better Value Stock Right Now?

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx is a leading resource for people with diabetes to find prescription savings and information, having helped almost 2.5 million Americans save more than $500 million on diabetes treatments to date. By offering invaluable access to affordable diabetes medicines and glucose monitors, accurate and digestible information about treatment options, and thorough research on diabetes and insulin prices, GoodRx is making it easier for people to afford their med.

GoodRx Surpasses $500 Million in Savings For Diabetic Americans

While the top- and bottom-line numbers for GoodRx Holdings, Inc. (GDRX) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

GoodRx Holdings, Inc. (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.06 per share a year ago.

GoodRx Holdings, Inc. (GDRX) Beats Q2 Earnings and Revenue Estimates

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), a leading resource for healthcare savings and information, has released its financial results for the second quarter 2023. Second Quarter 2023 Highlights Total revenue of $189.7 million, exceeding previously announced guidance Net income of $58.8 million1; Net income margin of 31.0% Adjusted Net Income2 of $28.4 million; Adjusted Net Income Margin2 of 15.0% Adjusted EBITDA2 of $53.5 million;.

GoodRx Reports Second Quarter 2023 Results

When GoodRx Holdings, Inc. NASDAQ: GDRX burst onto the scene in the middle of the pandemic, it brought promises of saving Americans money on their drug prescriptions. While consumers have indeed seen billions of dollars in savings, shareholders have seen nothing but losses.

More Good News Coming? GoodRx Spikes Ahead of Q2 Earnings

Aurora Innovation

BGC Group Inc

Genworth Financial

Hecla Mining

Joby Aviation

Nikola

Opendoor

Transocean

Rocket Lab USA

Roivant Sciences Ltd

Investors are even willing to dip into the cheap-stock territory outside the S&P 500 — and it's paying off handsomely so far.

11 Revived Stocks That Traded For $5 Or Less Are Now Worth Billions

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced Medicine Cabinet, a comprehensive solution designed to help consumers seamlessly manage their medications. Medicine Cabinet gives people easy-to-use tools to keep track of their prescriptions, get refill and daily pill reminders, find low prices, and earn rewards for staying on track. By making prescription management easier, smarter and more relevant, Medicin.

GoodRx Unveils Medicine Cabinet, A Better Way To Manage All Of Your Prescriptions

I recommended a hold until there are clearer signs of growth inflection in FY24, despite strong Q1 results. GoodRx Holdings is making strategic moves to strengthen direct connections with retail pharmacies, potentially boosting margins, but may strain relationships with Pharmacy Benefit Managers. Caution is advised for FY23 due to less-than-expected guidance, potential margin compression, and the shift in business model which may affect revenues.

GoodRx Holdings: Stay Cautious In FY23 Until Clear Signs Of Growth Inflection Appear

GoodRx offers a digital prescription platform. CVS Caremark is the nation's largest pharmacy benefits manager.

News for GoodRx Holdings Stock (GDRX)